Skip to main content
SpringerLink
Log in

CD4+CD25high regulatory cells in peripheral blood of NSCLC patients

  • Published:
Journal of Huazhong University of Science and Technology Aims and scope Submit manuscript

Summary

The proportion and changes of CD4+CD25high regulatory T cells (Trs) in peripheral blood of non-small cell lung cancer (NSCLC) patients were analyzed and their clinical significance explored. The peripheral blood was collected from 61 patients with NSCLC and 15 healthy controls. By using monoclonal antibodies, the blood samples were evaluated with the flow cytometry for lymphocyte subsets (CD3+, CD4+ and CD8+) and CD4+CD25high Tr cells. The results showed that the proportion of CD4+CD25high Tr cells in NSCLC group was significantly higher than in control group [(4.36±2.07) % vs (2.04±1.03) %, P<0.01]. The proportion of CD4+CD25high Tr cells in late stage was higher than that in early stage [stages: + II (2.26±0.6) %; stage III (3.28±1.38) %; stage IV (6.06±4.08) %] (P<0.05). Kaplan-Meier survival analysis revealed that the prognosis of the patients who had higher proportion of CD4+CD25high Tr cells in peripheral blood was worse (P=0.0026). In conclusion, the relative increase in CD4+CD25high Tr cells in peripheral blood may be related to immunosuppression and tumor progression in patients with NSCLC. This finding suggests that CD4+CD25+high Tr cells in peripheral blood of NSCLC may be positive for prognosis analysis. The use of depletion of the CD4+CD25high Tr cell therapy to treat NSCLC patients may be an effective strategy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol, 1995,155:1151–1164

    PubMed  CAS  Google Scholar 

  2. Dieckmann D, Plottner H, Berchtold S et al. Ex vivo isolation and characterization of CD4+CD25+T cells with regulatory properties from human blood. J Exp Med, 2001,193:1303–1310

    Article  PubMed  CAS  Google Scholar 

  3. Asano M, Toda M, Sakaguchi N et al. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med, 1996,184:387–396

    Article  PubMed  CAS  Google Scholar 

  4. Shevach E M. Certified professionals: CD4+CD25+ suppressor T cells. J Exp Med, 2001,193:F41–F46

    Article  PubMed  CAS  Google Scholar 

  5. Piccirillo C A, Shevach E M. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol, 2001,167:1137–1140

    PubMed  CAS  Google Scholar 

  6. Baecher-Allan C, Brown J A, Gordon J et al. CD4+CD25high regulatory cells in human peripheral blood. J Immunol, 2001,167:1245–1253

    PubMed  CAS  Google Scholar 

  7. Sasada T, Kimura M, Yoshida Y et al. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer, 2003,98:1089–1098

    Article  PubMed  Google Scholar 

  8. Rosenberg S A. Progress in human tumor immunology and immunotherapy. Nature, 2001,411:380–384

    Article  PubMed  CAS  Google Scholar 

  9. Tanaka H, Tanaka J, Kjaergaard J et al. Depletion of CD4+CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother, 2002,25:207–217

    Article  PubMed  CAS  Google Scholar 

  10. Diederichsen A C, Hjelmborg J B, Christensen P B et al. Prognostic value of the CD4+/CD8+ ratio of the tumor infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumor cells. Cancer Immunol Immunother, 2003,52:423–428

    Article  PubMed  CAS  Google Scholar 

  11. Niu H Q, Dong Z, Dong F Y et al. Experimental and clinical research of dendritic cell and syngeneic immunotherapy of brain glioma. Chinese-German J Clin Oncol, 2004,3:147–150

    Google Scholar 

  12. Nagai H, Horikawa T, Hara I et al. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer. Exp Dermatol, 2004,13:613–620

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Huazhong University of Science and Technology, Wuhan, 430023, China

    Liu Li  (刘莉) (female, Associate Professor) & Ding Qian  (丁乾)

  2. Stem Cell Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430023, China

    Yao Junxia  (姚军霞) & Huang Shiang  (黄士昂)

Authors
  1. Liu Li  (刘莉)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yao Junxia  (姚军霞)
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ding Qian  (丁乾)
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Huang Shiang  (黄士昂)
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This project was supported by grants from National Science Fundation for Distinguished Young Scholars (No. 30225038) and The National Basic Research Program (No.2001CB5101).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liu, L., Yao, J., Ding, Q. et al. CD4+CD25high regulatory cells in peripheral blood of NSCLC patients. J. Huazhong Univ. Sc. Technol. 26, 548–551 (2006). https://doi.org/10.1007/s11596-006-0516-5

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-006-0516-5

Key words

Search

Navigation